Literature DB >> 18573187

Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?

A M Gallagher1, S Rietbrock, J Plumb, T P van Staa.   

Abstract

BACKGROUND: Practice guidelines recommend long-term stroke prophylaxis in patients with chronic atrial fibrillation (cAF).
OBJECTIVES: To examine treatment initiation and persistence and factors that influence the choice of cAF treatment. PATIENTS/
METHODS: This study used the General Practice Research Database, including computerized medical records of general practitioners in the UK. Patients aged 40+ years with cAF after 1 January 2000 were included. Cox proportional hazards regression models evaluated initiation and treatment continuation over time of warfarin and aspirin. Treatment discontinuation was defined as no repeat prescription within a three-month period after the expected end of the treatment course.
RESULTS: The study population included 41 910 cAF patients. Elderly patients (aged 85+) were less likely to start warfarin [relative rate (RR) = 0.16, 95% confidence interval (CI) 0.15-0.18] and more likely to start aspirin (RR = 1.66, 95% CI 1.47-1.88) than patients aged 40-64 years. A history of dementia (RR = 0.28, 95% CI 0.17-0.44) and falls (RR = 0.76, 95% CI 0.70-0.83) also reduced the likelihood of warfarin initiation. Adjusting for age and gender, higher stroke risk (CHADS2 score) was not found to be associated with initiation of warfarin or aspirin contrary to current guidelines recommendations. One-year persistence was 70% for warfarin and 50% for aspirin. Treatment persistence was higher in elderly patients using warfarin and aspirin. A higher CHADS(2) score was associated with improved persistence only with warfarin.
CONCLUSIONS: The low likelihood of patients with cAF in general practice remaining on treatment long-term indicates that not all benefits as observed in clinical trials may be achieved in usual clinical practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573187     DOI: 10.1111/j.1538-7836.2008.03059.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  69 in total

Review 1.  Almanac 2013: novel non-coronary cardiac interventions.

Authors:  Pascal Meier; Olaf Franzen; Alexandra J Lansky
Journal:  Wien Klin Wochenschr       Date:  2013-12       Impact factor: 1.704

Review 2.  Benefits and pitfalls of cardiovascular medication in seniors.

Authors:  Hana Matejovska Kubesova; Pavel Weber; Hana Meluzinova; Katarina Bielakova; Jan Matejovsky
Journal:  Wien Klin Wochenschr       Date:  2013-07-12       Impact factor: 1.704

3.  Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Authors:  Francesco Violi; Daniele Pastori
Journal:  Intern Emerg Med       Date:  2019-06-27       Impact factor: 3.397

4.  Left atrial appendage exclusion for atrial fibrillation: does the protection from stroke prevail in the long-term?

Authors:  Vaibhav R Vaidya; Roshini Asirvatham; Jason Tri; Samuel J Asirvatham
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

5.  Assessment of Shared Decision-making for Stroke Prevention in Patients With Atrial Fibrillation: A Randomized Clinical Trial.

Authors:  Marleen Kunneman; Megan E Branda; Ian G Hargraves; Angela L Sivly; Alexander T Lee; Haeshik Gorr; Bruce Burnett; Takeki Suzuki; Elizabeth A Jackson; Erik Hess; Mark Linzer; Sarah R Brand-McCarthy; Juan P Brito; Peter A Noseworthy; Victor M Montori
Journal:  JAMA Intern Med       Date:  2020-07-20       Impact factor: 21.873

6.  Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.

Authors:  Tomas Forslund; Björn Wettermark; Paul Hjemdahl
Journal:  Eur J Clin Pharmacol       Date:  2015-11-27       Impact factor: 2.953

7.  Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism.

Authors:  Patrick P Kneeland; Margaret C Fang
Journal:  Patient Prefer Adherence       Date:  2010-03-24       Impact factor: 2.711

Review 8.  [Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?]

Authors:  P Bahrmann; M Christ
Journal:  Herz       Date:  2018-05       Impact factor: 1.443

9.  Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: a Danish survey.

Authors:  Axel Brandes; Mikkel Overgaard; Liane Plauborg; Christian Dehlendorff; Frede Lyck; Jørgen Peulicke; Søren Vinther Poulsen; Steen Husted
Journal:  Clin Cardiol       Date:  2013-05-13       Impact factor: 2.882

10.  Selection of medical diagnostic codes for analysis of electronic patient records. Application to stroke in a primary care database.

Authors:  Martin C Gulliford; Judith Charlton; Mark Ashworth; Anthony G Rudd; Andre Michael Toschke
Journal:  PLoS One       Date:  2009-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.